Condition: Kidney Transplant Rejection · Sponsor: Medeor Therapeutics, Inc.
The primary objective of this study is to demonstrate the safety and efficacy of cellular immunotherapy with MDR-101 for induction of functional immune tolerance in recipients of human leukocyte antigen (HLA)-matched, living donor kidney transplants.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Loma Linda University Medical Center | Loma Linda, California, United States | — |
| USC | Los Angeles, California, United States | — |
| Stanford University Medical Center | Stanford, California, United States | — |
| University of Colorado Denver | Aurora, Colorado, United States | — |
| Yale University | New Haven, Connecticut, United States | — |
| Georgetown University Medical Center | Washington D.C., District of Columbia, United States | — |
| Mayo Clinic Hospital | Jacksonville, Florida, United States | — |
| Loyola University Medical Center | Maywood, Illinois, United States | — |
| Mayo Clinic | Rochester, Minnesota, United States | — |
| RWJBarnabas Health | Orange, New Jersey, United States | — |
| Upstate University Hospital | Syracuse, New York, United States | — |
| University Hospitals Cleveland Medical Center | Cleveland, Ohio, United States | — |
+ 7 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03363945